11:30 AM - 12:00 PM ET
One year of sickle cell gene therapy commercialization: What have we learned, and where are we going?
In December 2023, the FDA approved the first gene therapies to treat sickle cell disease — milestones both for the blood disorder and for gene therapies overall. In the year since, patients have started to get the life-changing treatments. And the companies making the treatment have worked on charting a path towards profitability. We’re gathering experts and stakeholders to reflect on lessons learned, and the next steps on the road.